Mechanism of Action
Chondrocyte Gene Activation
The Ala-Glu-Asp sequence binds to histone-associated chromatin structures in chondrocytes, activating transcription of the major cartilage matrix components: type II collagen (the primary structural protein of hyaline cartilage), aggrecan (the primary proteoglycan), and link protein. These genes are progressively silenced by epigenetic mechanisms in aging chondrocytes and in osteoarthritic tissue, where the balance shifts from matrix synthesis to catabolic matrix metalloproteinase (MMP) activity. Cartalax's chromatin-activating effect reverses this balance, restoring anabolic matrix gene expression.
Anti-catabolic and Anti-apoptotic Effects
In addition to activating anabolic gene programs, Cartalax reduces expression of MMP-3, MMP-13, and ADAMTS-5, the primary enzymes responsible for degrading collagen and aggrecan in osteoarthritic cartilage. It also promotes Bcl-2 anti-apoptotic signaling in chondrocytes, reducing the cell death that depletes the chondrocyte population in aging joints. The combination of increased matrix synthesis, decreased matrix degradation, and decreased chondrocyte apoptosis represents a comprehensive anabolic shift in cartilage biology.
Research Summary
Osteoarthritis and Cartilage Aging
EmergingKhavinson's group published data showing Cartalax normalized chondrocyte gene expression profiles in aged and osteoarthritic rodent cartilage, with increased COL2A1 and ACAN transcription and reduced MMP expression. Histological studies showed reduced articular surface fibrillation and subchondral bone changes in treated versus control animals. Functional assessments showed improved gait symmetry and reduced pain behavior in osteoarthritis models.
Calculate your Cartalax dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Osteoarthritis / joint longevity | 5-10 mcg/day SC | 10 days; 1-2x/year | Subcutaneous |
| Joint injury recovery | 10 mcg/day SC | 10-20 days | Subcutaneous |
| Combination Khavinson protocol | 5 mcg/day | 10 days concurrent | SC alongside Epithalon, Thymalin |
Cartalax can be stacked with BPC-157 for joint protocols, BPC-157 promotes tendon/ligament healing and growth factor upregulation; Cartalax specifically restores chondrocyte gene programs. They address complementary aspects of joint tissue health.
Interactions
Safety Profile
Cartalax has an excellent safety profile consistent with all Khavinson tripeptide bioregulators. No serious adverse events have been documented in published research or clinical reports. The microgram dosing and short half-life minimize systemic exposure. Local SC injection reactions are occasional and mild. No carcinogenicity or organ toxicity has been observed in animal studies. As with other bioregulators, theoretical caution in active autoimmune arthritis (ankylosing spondylitis, rheumatoid arthritis) is warranted given the cell-activating mechanism, though stimulating cartilage matrix synthesis is generally beneficial even in these contexts. Not WADA prohibited. Not FDA approved. Not scheduled.
References
- [1]Khavinson VKh et al. "Peptide bioregulators normalize chondrocyte gene expression in aging and osteoarthritis." Bull Exp Biol Med. 2015;158(5):607-610.
- [2]Khavinson VKh, Linkova NS. "Mechanism of peptide regulation of genome." Bull Exp Biol Med. 2010;150(1):10-13.